Today, May 27, is the last day of trading in IRLAB’s share before share split
IRLAB announces that today, Monday May 27, 2019, is the last day of trading in the company’s share before the share split. Tomorrow, Tuesday May 28, 2019, is the first day of trading in the share after the split. This means that the share price will reflect the effect of the split from May 28, 2019.
The terms for the split are a 5:1 split where each current share (1) is divided into five (5) shares of the same kind. For more information regarding the split, see the previous press release ”IRLAB announces share split” from May 17, 2019. The share split was resolved at IRLAB Therapeutics AB’s Annual General Meeting on April 25, 2019.
The split of the company's shares takes place automatically via Euroclear Sweden AB and shareholders do not need to take any action.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
IRLAB is a Swedish biotech company focused on Parkinson's disease. The company's clinical Phase II candidates, IRL752 and IRL790, intend to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (LIDs), psychosis and dementia. Through the proprietary ISP (Integrative Screening Process) research platform, IRLAB discovers and develops drug candidates for central nervous system (CNS) related diseases where big growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, email@example.com, +46 (0)8‑528 00 399. More information on www.irlab.se.